Abstract
We analyzed the outcome of patients aged more than 60 included in a multicenter trial in newly diagnosed acute promyelocytic leukemia (APL93 trial), which tested the role of early addition of chemotherapy to all trans retinoic acid (ATRA) and of maintenance with ATRA and/or low-dose chemotherapy. In total, 129/533 (24.2%) patients included in this trial were older than 60. The CR rate was 86% in patients older than 60 as compared to 94.5% in younger patients (P=0.0014), due to a higher incidence of early deaths in elderly patients. The 4-year incidence of relapse was 15.6% in adults older than 60 and 23.2% in younger adults although most elderly patients received less intensive consolidation chemotherapy. However, 18.6% of the patients older than 60 years who achieved CR died in CR, mainly from sepsis during consolidation course or maintenance treatment, as compared to 5.7% of younger adults (P<0.001). Thus, overall 4-year survival of elderly patients was 57.8% as compared to 78% in younger adults (P<0.0001). APL in elderly patients appears as sensitive to ATRA-Chemotherapy based regimen as in younger adults. Less favorable outcome is mainly due to an increase of early deaths and to toxicity of consolidation treatment, strongly suggesting a beneficial role for less intensive consolidation chemotherapy and possibly introduction of arsenic derivates in the treatment of APL in the elderly.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fenaux P, Chomienne C, Degos L . All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13–25.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200.
Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85: 1202–1206.
Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C et al. Programa de Estudio y Traitmiento de las Hemopatias Malignas. Risk-adapted treatment of acute promyelocytic leukemia with all-transretinoic acid and anthracycline monochemotherapy: a multicenter study the PETHEMA group. Blood 2004; 103: 1237–1243.
Sanz M, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004, August 3 [E-pub ahead of print].
Warrell Jr RP, Maslak P, Eardley A, Heller G, Miller Jr WH, Frankel SR . Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994; 8: 929–933.
de Botton S, Coiteux V, Chevret S, Rayon C, Vilmer E, Sanz M et al. Outcome of childhood acute promyelocytic leukemia with all-trans retinoic acid and chemotherapy. J Clin Oncol 2004; 22: 1404–1412.
Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F et al. Treatment of elderly patients (>or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA w<ith ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17: 1085–1090.
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–458.
Fenaux P, Pollet JP, Vandenbossche-Simon JL . Treatment of acute promyelocytic leukemia. A report on 70 cases. Leukemia Lymphoma 1991; 4: 239–246.
Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD . Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116–1122.
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH . Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143.
Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wormann B et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999; 17: 3569–3576.
Estey E, Thall PF, Pierce S, Kantarjian H, Keating M . Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997; 15: 483–490.
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324.
Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 2002; 99: 3136–3143.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Ades, L., Chevret, S., De Botton, S. et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 19, 230–233 (2005). https://doi.org/10.1038/sj.leu.2403597
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403597
Keywords
This article is cited by
-
Safety and efficacy of arsenic trioxide and all-trans retinoic acid therapy in acute promyelocytic leukemia patients with a high risk for early death
Annals of Hematology (2020)
-
Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide
Journal of Cancer Research and Clinical Oncology (2020)
-
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide—an International Collaborative Study
Leukemia (2020)
-
Management of patients with acute promyelocytic leukemia
Leukemia (2018)
-
Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy
Leukemia (2018)